Retigabine(旅行社协会》)。

文章的细节

引用

复制到剪贴板

Fatope莫

Retigabine(旅行社协会》)。

IDrugs。2001年1月,4 (1):93 - 8。

PubMed ID

16034707 (在PubMed

]

文摘

旅行社正在发展retigabine,氨基甲酸乙酯和选择性钾通道揭幕战,治疗复杂部分发作。二期试验开始[249117],一项多中心安慰剂对照dosage-finding研究已经开始在欧洲和澳大利亚[392702]。Retigabine也进行第二阶段测试在德国,瑞士、俄罗斯和美国的潜在的治疗癫痫[323383]。二期试验显示>发作频率减少50%在12个35难治性癫痫患者[373379]。第一阶段临床试验癫痫是成功完成在德国1995年[180371]。单个和多个剂量试验证明了复合的耐受性和有利的药代动力学行为[264306]。化合物表现出良好的兼容性和展品的反义抗惊厥效果各种临床癫痫模型(250565、299344)。的副作用轻度至中度疲劳,疲劳和恶心观察[276123]。retigabine类似于丙戊酸钠的范围的活动,但它的力量是更大的和毒性降低[373379]。retigabine的作用机制可能是多因素疾病。 Research has shown that retigabine acts as a selective K+ channel opener in neuronal cells and this can be expected to contribute to its anticonvulsant effect [273670]. In addition it demonstrates potentiation of GABA transmission and possibly also weak modulation of sodium and calcium channels [299344]. Retigabine also has neuroprotective activity with potential for the treatment of stroke and neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease and multiple sclerosis [249381]. In February 2000, Lehman Brothers predicted product launch could be as early as 2002 for epilepsy in the US [357788]. In February 1999, Lehman Brothers predicted that the first major launch date of the drug would be 2003, and the year of peak sales to be 2011 [319225].

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Ezogabine